Navigation Links
New Deloitte Recap Report Identifies Strategies to Help Reduce Development Times and Increase Success Rates for Cancer Drugs
Date:11/2/2010

SAN FRANCISCO, Nov. 2, 2010 /PRNewswire/ -- Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion in oncology drugs while transforming the medical outlook for many cancer patients.

"Scientific innovation has brought measurable rewards such as reduced development times, higher success rates for cancer drugs, and increased investment and activity across the biopharmaceutical industry," said Lisa Natanson, senior analyst, Deloitte Recap LLC. "We see clear patterns of successful drug development from this study of a defined set of biotechnology companies that have produced innovative cancer drugs in the last decade."

By analyzing the drug development patterns of the Deloitte Recap BioPortfolio Index (RBI) companies, a select group of more than 150 biotechnology companies that have been tracked and benchmarked for more than a decade, Deloitte identified the following key findings:

  • FDA-approved oncology compounds all heavily utilized at least one (and some as many as four) special U.S. regulatory mechanisms, such as Fast Track designation, Orphan Drug status, or Accelerated Approval, to speed clinical development and reduce FDA transit times.
  • Orphan indications served as an initial market entry point to billion dollar markets followed by label expansion efforts to broaden the patient populations.
  • Innovative agents, such as those targeting receptor tyrosine kinases, achieved up to 31 percent approval success rates.

"Overall, the findings of this report demonstrate that the biotech industry is having a measurable impact on developing new therapies in the 'war on cancer,'" concluded Matthew Hudes, national managing principal of the biotechnology practice for Deloitte Consulting LLP.

To register for a copy of this report, visit http://www.recap.com/whitepaper.

About Deloitte Recap

Deloitte Recap LLC was originally founded as Recombinant Capital, Inc. in 1988 by Mark Edwards and based in the San Francisco Bay Area.  In July 2008, Recombinant Capital, Inc. was purchased by a subsidiary of Deloitte LLP and the business is now known as Deloitte Recap LLC.  

As used in this document, "Deloitte" means Deloitte LLP and its subsidiaries.   Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.


'/>"/>
SOURCE Deloitte
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DUSA Pharmaceuticals Named to Deloittes 2010 Technology Fast 500 List of Fastest Growing Companies in North America
2. Virtual Radiologic Ranked 264th Fastest-Growing Company in North America on Deloittes 2010 Technology Fast 500™
3. China Medical Technologies Announces its Subsidiary, GP Medical, Ranked Sixth in Deloitte Technology Fast 50 China 2010 Program
4. Accuray Ranked Number 113 Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
5. Genoptix Ranked 41st Fastest-Growing Company in North America on Deloittes 2010 Technology Fast 500™
6. Deloitte Issue Brief: Mobile Personal Health Records May Offer Consumers Key to Technology-Enabled Self-Care
7. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
8. Time to Blow Up the Pharmaceutical Sales Model? New Deloitte Debate
9. Health Care Retail Clinics Continue Gradual Expansion Through 2012: Deloitte Center for Health Solutions Report
10. Deloitte Recap Launches New Solution for Clinical Development
11. Deloitte Report: Pharmaceutical Companies Patent Cliff Could Bolster Mergers and Acquisitions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Report Details ... Alzheimer,s Disease Therapeutics and ... our new study reveals trends, R&D progress, and predicted ... the Alzheimer,s disease therapeutics and diagnostics market. Our new ... - How is the Alzheimer,s disease therapeutics and diagnostics ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 ... and Others The global anti-obesity drugs market ... first half of the forecast period and CAGR of 38.7% in ... to grow at a CAGR of 32.8% from 2016 to 2027. ... in 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... -- James Gilbart , ... 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ...      ... in a supplement to European Oncology & Haematology ... by James Gilbart and Axel ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser ... Cancer Institute. For Betsy, the clinical trial has been life-saving as she has ... worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is ... life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater ... spent her career as an educator interacting with countless women who had little knowledge ...
(Date:1/20/2017)... ... ... a fine examination of how God handles sin, including how to let go of ... who, for over ten long years has been waiting to release this powerful insight about ... has been serving the Lord for over twenty years, and he has been preaching and ...
(Date:1/20/2017)... ... ... and enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” is ... a devoted woman of faith. , “Becoming a parent changes you. In my case, ... for years, but actually doing it might have been a while in coming if it ...
(Date:1/20/2017)... ... , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation of ... Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native who ... Hardy , “While sitting up in bed, I felt a pounding headache. It was ...
Breaking Medicine News(10 mins):